CRISPR Therapeutics (CRSP) Stock Forecast, Price & News

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 1 sell rating, 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRSP shares.
View CRSP analyst ratings or view top-rated stocks.

18 Wall Street research analysts have issued twelve-month target prices for CRISPR Therapeutics' stock. Their CRSP share price forecasts range from $39.00 to $123.00. On average, they predict the company's stock price to reach $74.89 in the next year. This suggests a possible upside of 15.8% from the stock's current price.
View analysts price targets for CRSP or view top-rated stocks among Wall Street analysts.

CRISPR Therapeutics' stock was trading at $40.65 on January 1st, 2023. Since then, CRSP stock has increased by 59.1% and is now trading at $64.66.
View the best growth stocks for 2023 here.

CRISPR Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 12,430,000 shares, a decrease of 5.8% from the April 30th total of 13,200,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the short-interest ratio is currently 9.5 days. Approximately 16.4% of the company's shares are sold short.
View CRISPR Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our CRSP earnings forecast.

CRISPR Therapeutics AG (NASDAQ:CRSP) posted its quarterly earnings data on Monday, May, 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($1.64) by $0.97. The firm earned $100 million during the quarter, compared to analyst estimates of $24.33 million. CRISPR Therapeutics had a negative net margin of 516.43% and a negative trailing twelve-month return on equity of 26.64%. CRISPR Therapeutics's revenue was up 10538.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.32) earnings per share.

ETFs with the largest weight of CRISPR Therapeutics (NASDAQ:CRSP) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), Loncar Cancer Immunotherapy ETF (CNCR), Global X Genomics & Biotechnology ETF (GNOM), AXS Green Alpha ETF (NXTE), iShares Genomics Immunology and Healthcare ETF (IDNA) and Horizon Kinetics Medical ETF (MEDX).

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

CRISPR Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (10.16%), Sumitomo Mitsui Trust Holdings Inc. (5.05%), Nikko Asset Management Americas Inc. (5.04%), BlackRock Inc. (3.55%), FMR LLC (2.71%) and State Street Corp (2.52%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho.
View institutional ownership trends.

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRSP stock can currently be purchased for approximately $64.66.

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $5.10 billion and generates $100.26 million in revenue each year. The company earns $-650,170,000.00 in net income (profit) each year or ($6.72) on an earnings per share basis.

The company employs 473 workers across the globe.

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.